{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:16:24Z","timestamp":1794438984603,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["CKTO 2001\u201304"],"award-info":[{"award-number":["CKTO 2001\u201304"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2012-5719"],"award-info":[{"award-number":["UL2012-5719"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41416-018-0310-8","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T07:36:13Z","timestamp":1539934573000},"page":"1067-1074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":258,"title":["Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy"],"prefix":"10.1038","volume":"119","author":[{"name":"for the PORTEC Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. G.","family":"Wortman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Creutzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Putter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"J\u00fcrgenliemk-Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Jobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. C. H. W.","family":"Lutgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"van der Steen-Banasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W. M.","family":"Mens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Slot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C. Stenfert","family":"Kroese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"van Triest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. W.","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Stelloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. L. J.","family":"van Putten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. T. H. B. M","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Nout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"310_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","volume":"387","author":"P Morice","year":"2016","unstructured":"Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N. & Darai, E. Endometrial cancer. Lancet 387, 1094\u20131108 (2016).","journal-title":"Lancet"},{"key":"310_CR2","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","volume":"355","author":"CL Creutzberg","year":"2000","unstructured":"Creutzberg, C. L. et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355, 1404\u20131411 (2000).","journal-title":"Lancet"},{"key":"310_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ijrobp.2011.04.013","volume":"81","author":"CL Creutzberg","year":"2011","unstructured":"Creutzberg, C. L. et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 81, 631\u2013638 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"310_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","volume":"92","author":"HM Keys","year":"2004","unstructured":"Keys, H. M. et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 92, 744\u2013751 (2004).","journal-title":"Gynecol. Oncol."},{"key":"310_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0140-6736(08)61767-5","volume":"373","author":"P Blake","year":"2009","unstructured":"Blake, P. et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373, 137\u2013146 (2009).","journal-title":"Lancet"},{"key":"310_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","volume":"375","author":"RA Nout","year":"2010","unstructured":"Nout, R. A. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375, 816\u2013823 (2010).","journal-title":"Lancet"},{"key":"310_CR7","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2008.20.2424","volume":"27","author":"RA Nout","year":"2009","unstructured":"Nout, R. A. et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J. Clin. Oncol. 27, 3547\u20133556 (2009).","journal-title":"J. Clin. Oncol."},{"key":"310_CR8","first-page":"1638","volume":"48","author":"RA Nout","year":"2012","unstructured":"Nout, R. A. et al. Five-year quality of life of endometrial cancer patients treated in the randomised post operative radiation therapy in endometrial. Cancer (PORTEC-2) Trial Comp. Norm. data. Eur. J. C. 48, 1638\u20131648 (2012).","journal-title":"Cancer (PORTEC-2) Trial Comp. Norm. data. Eur. J. C."},{"key":"310_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ijrobp.2015.08.023","volume":"93","author":"SM Boer de","year":"2015","unstructured":"de Boer, S. M. et al. Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: results from the randomized PORTEC-2 trial. Int. J. Radiat. Oncol. Biol. Phys. 93, 797\u2013809 (2015).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"310_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67\u201373 (2013).","journal-title":"Nature"},{"key":"310_CR11","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","volume":"22","author":"E Stelloo","year":"2016","unstructured":"Stelloo, E. et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin. Cancer Res. 22, 4215\u20134224 (2016).","journal-title":"Clin. Cancer Res."},{"key":"310_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/bjc.2015.190","volume":"113","author":"A Talhouk","year":"2015","unstructured":"Talhouk, A. et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer 113, 299\u2013310 (2015).","journal-title":"Br. J. Cancer"},{"key":"310_CR13","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1016\/j.ejca.2014.07.014","volume":"50","author":"T Bosse","year":"2014","unstructured":"Bosse, T. et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur. J. C. 50, 2602\u20132610 (2014).","journal-title":"Eur. J. C."},{"key":"310_CR14","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.ejca.2015.05.015","volume":"51","author":"T Bosse","year":"2015","unstructured":"Bosse, T. et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer-A pooled analysis of PORTEC 1 and 2 trials. Eur. J. C. 51, 1742\u20131750 (2015).","journal-title":"Eur. J. C."},{"key":"310_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(09)60678-4","volume":"373","author":"H Kitchener","year":"2009","unstructured":"Kitchener, H. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373, 125\u2013136 (2009).","journal-title":"Lancet"},{"key":"310_CR16","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/jnci\/djn397","volume":"100","author":"P Benedetti Panici","year":"2008","unstructured":"Benedetti Panici, P. et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl. Cancer Inst. 100, 1707\u20131716 (2008).","journal-title":"J. Natl. Cancer Inst."},{"key":"310_CR17","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.ijrobp.2011.04.014","volume":"82","author":"B Sorbe","year":"2012","unstructured":"Sorbe, B. et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma- a prospective randomized study. Int. J. Radiat. Oncol. Biol. Phys. 82, 1249\u20131255 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"310_CR18","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2010.32.4590","volume":"29","author":"RA Nout","year":"2011","unstructured":"Nout, R. A. et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1). Trial J. Clin. Onc 29, 1692\u20131700 (2011).","journal-title":"Trial J. Clin. Onc"},{"key":"310_CR19","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1111\/IGC.0b013e3181f5c688","volume":"20","author":"GM Thomas","year":"2010","unstructured":"Thomas, G. M. A role for adjuvant radiation in clinically early carcinoma of the endometrium? Int. J. Gynecol. Cancer 20, S64\u2013S66 (2010).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"310_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/jnci\/dju402","volume":"107","author":"DN Church","year":"2015","unstructured":"Church, D. N. et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J. Natl. Cancer Inst. 107, 402 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"310_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdw542","volume":"28","author":"E Stelloo","year":"2017","unstructured":"Stelloo, E. et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann. Oncol. 28, 96\u2013102 (2017).","journal-title":"Ann. Oncol."},{"key":"310_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/jnci\/djt144","volume":"105","author":"AG Zeimet","year":"2013","unstructured":"Zeimet, A. G. et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J. Natl. Cancer Inst. 105, 1142\u20131150 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"310_CR23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/bjc.2016.235","volume":"115","author":"LJ Putten van der","year":"2016","unstructured":"van der Putten, L. J. et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br. J. Cancer 115, 716\u2013724 (2016).","journal-title":"Br. J. Cancer"},{"issue":"2","key":"310_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/modpathol.2015.147","volume":"29","author":"Inge C Van Gool","year":"2016","unstructured":"Van Gool I. C., et al. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Mod Pathol 29, 174-181 (2016).","journal-title":"Modern Pathology"},{"key":"310_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1006\/gyno.2002.6825","volume":"87","author":"DE Cohn","year":"2002","unstructured":"Cohn, D. E. et al. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol. Oncol. 87, 243\u2013246 (2002).","journal-title":"Gynecol. Oncol."},{"key":"310_CR26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ygyno.2004.11.033","volume":"96","author":"JM Briet","year":"2005","unstructured":"Briet, J. M. et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol. Oncol. 96, 799\u2013804 (2005).","journal-title":"Gynecol. Oncol."},{"key":"310_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S0360-3016(01)02710-9","volume":"52","author":"AN Scholten","year":"2002","unstructured":"Scholten, A. N., Creutzberg, C. L., Noordijk, E. M. & Smit, V. T. Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system. Int. J. Radiat. Oncol. Biol. Phys. 52, 1067\u20131074 (2002).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"310_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/cncr.20040","volume":"100","author":"AN Scholten","year":"2004","unstructured":"Scholten, A. N., Smit, V. T., Beerman, H., van Putten, W. L. & Creutzberg, C. L. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 100, 764\u2013772 (2004).","journal-title":"Cancer"},{"key":"310_CR29","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/PAS.0b013e31815a04f5","volume":"32","author":"E Manion","year":"2008","unstructured":"Manion, E., Cohen, M. B. & Weydert, J. Mandatory second opinion in surgical pathology referral material: clinical consequences of major disagreements. Am. J. Surg. Pathol. 32, 732\u2013737 (2008).","journal-title":"Am. J. Surg. Pathol."},{"key":"310_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/annonc\/mdx753","volume":"29","author":"SM Boer de","year":"2018","unstructured":"de Boer, S. M. et al. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann. Oncol. 29, 424\u2013430 (2018).","journal-title":"Ann. Oncol."},{"key":"310_CR31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","volume":"95","author":"R Maggi","year":"2006","unstructured":"Maggi, R. et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br. J. Cancer 95, 266\u2013271 (2006).","journal-title":"Br. J. Cancer"},{"key":"310_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","volume":"108","author":"N Susumu","year":"2008","unstructured":"Susumu, N. et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol. Oncol. 108, 226\u2013233 (2008).","journal-title":"Gynecol. Oncol."},{"key":"310_CR33","unstructured":"Randall M. Abstract LBA-1: A phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel\/carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: a Gynecology Oncology Group study. Int. J. Radiat. Oncol. Biol. Phys. (2017)."},{"key":"310_CR34","unstructured":"ISRCTNregistry. PORTEC-4a: Randomised trial of standard or molecular profile-based recommendation for radiotherapy after surgery for women with early stage endometrial cancer. http:\/\/www.isrctn.com\/ISRCTN11659025 (2016); Site visited on 17-10-2017."},{"key":"310_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ygyno.2018.07.020","volume":"151","author":"BG Wortman","year":"2018","unstructured":"Wortman, B. G. et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial. Gynecol. Oncol. 151, 69\u201375 (2018).","journal-title":"Gynecol. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0310-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0310-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0310-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:03:38Z","timestamp":1684602218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0310-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0310-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"12 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial protocol was approved by the Dutch Cancer Society (CKTO 2001\u201304) and the Ethics Committees of participating centres. Written informed consent was given by all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"The PORTEC-2 study was supported by a grant from the Dutch Cancer Society (CKTO 2001\u201304).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Funding:"}},{"value":"All authors consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication:"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}]}}